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Autism spectrum disorders (ASD) are classiﬁed as neurological developmental disorders. Several studies have been carried out
toﬁndacandidatebiomarkerlinkedtothedevelopmentofthesedisorders,butuptodatenoreliablebiomarkerisavailable.Mass
spectrometrytechniqueshavebeenusedforproteinproﬁlingofbloodplasma ofchildren withsuchdisordersinorder toidentify
proteins/peptides that may be used as biomarkers for detection of the disorders. Three differentially expressed peptides with
mass–charge (m/z) values of 2020±1, 1864±1 and 1978±1Da in the heparin plasma of children with ASD that were
signiﬁcantly changed as compared with the peptide pattern of the non-ASD control group are reported here. This novel set of
biomarkers allows for a reliable blood-based diagnostic tool that may be used in diagnosis and potentially, in prognosis of ASD.
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Introduction
Autism spectrum disorders (ASD) are characterized by impair-
ments in social orientation, communication and repetitive or
restricted patterns of interests or behaviors appearing during
the ﬁrst 3 years of life with onset from birth or gradually in a
regressive process from the end of the ﬁrst year but mainly
during the second year
1,2 and is in Diagnostic and Statistical
Manual of Mental Disorders (DSM)-IV classiﬁed as a
developmental disorder.
3 The pathogenesis of ASD is not
yet known. Diagnosis is based on DSM-IV criteria and
consists of a triad of symptoms, including social impairment,
language disturbances and a rigid adherence to sameness.
In children diagnosed with ASD there is a spectrum of
severity of these symptoms reﬂecting a variation in cognitive
development ranging from above average to intellectual
disability.
4,5 Boys are 4–5 times more likely than girls to have
autism.
6 Although the genetic determinants of ASD are so far
largely unknown a recent report describes enrichments in
different gene sets known to be linked to ASD.
7 Pathophysiol-
ogy of ASD involves affected cellular and neuronal develop-
ment and function possibly associated with abnormal patterns
of proteins/peptides in the blood and the cerebrospinal
ﬂuid,
8–10 increased levels of neurotransmitter serotonin and
b-endorphin,
11–13 low levels of melatonin,
14 increased levels
of opioid,
15 high levels of homocysteine,
16 Ca
2þ channel
deﬁciency,
17 gene–environment interactions,
18 altered levels
of serine protease prolyl endopeptidase activity,
19 low plasma
levels of the neuropeptide hormone oxytocin,
20 elevated
immune response
21 and abnormal activation of the comple-
ment system.
22–24 Complement-system activation in re-
sponse to a foreign antigen or a genetic disorder leads
to degradation of complement protein C to C3a and C3b
protein fragments with molecular masses of about 9kDa
and177kDa,respectively.
25ComplementfactorI-mediated
cleavage of the C3b a-chain liberates three protein
fragments with molecular masses of 68, 43 and 2kDa,
26
of which the last one is known as C3f.
27,28 The C3f peptide
has been shown to have weak spasmogenic and anaphy-
latoxic functions and enhances vascular permeability as
s h o w ni ng u i n e ap i gs k i nt e s t s .
28 Further degradation of
C3f to C3f-desArg mediated by carboxypeptidase N was
shown to result in stronger spasmogenic and anaphylatoxic
properties.
28 Figure 1 illustrates the location of the C3f
domain in the crystal structure of the C3 protein.
29
Detection of low-molecular-weight peptides by proteomic
proﬁling of blood plasma and cerebrospinal ﬂuid may reveal
altered protein/peptide patterns associated with diseases
anddisorders.
30–33Inarecentstudy,adultswithAsperger’s
syndrome was shown to exhibit sex-speciﬁc expression of
serum biomarkers.
33 Previous attempts to ﬁnd a reliable
biomarkerforASDbyuseofproteomicsandprotein/peptide
proﬁling have led to a set of potential biomarkers. A pro-
teomic study on autopsied autism brains using 2-D gel elec-
trophoresis revealed a single-nucleotide polymorphism in
glyoxalase I.
34 Another proteomic study of serum from children
with autism showed differential expression of apolipoproteins
and other components of complement proteins.
35
In this study, we undertook a proteomic approach using
surface-enhanced laser desorption/ionization time-of-ﬂight
(SELDI TOF) mass spectrometry to compare peptide proﬁles
of blood plasma from children with ASD and control children
(Table1)withthe aimofdiscoveringnovelpeptidebiomarkers
with diagnostic utility and tounderstand the roleof thesein the
pathophysiology of ASD.
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Participants. Thirty-two children with ASD and thirty-one
healthy control children were initially selected for this study.
Children in the ASD group were recruited from the autism
rehabilitation centre at the University of Social Welfare and
Rehabilitation Sciences in Tehran, Iran. After receiving the
informed consent from the parents, blood samples were
collected. All children with ASD were examined by clinical
experts on autism. A child psychiatrist examined all the
children who were also examined by a child neurologist or a
child psychiatrist. All consultants agreed on the diagnosis
of autism according to the DSM-IV criteria.
3 However,
diagnostic procedures applied in Europe and USA/Canada
using the Autism Diagnostic Observation Schedule
36 and the
Autism Diagnostic Interview—Revised
37 were not used in the
diagnostic process applied in Iran. This shortcoming was met
by long clinical experience by the child neurologist/child
psychiatrist who was aware of the core behaviors in autism
stated by the American Academy of Pediatrics in its Embargo
from 2007.
38 All children in the ASD group were diagnosed
as having autistic syndrome (infantile or Kanner autism) with
varying degree of mental retardation but no information about
other psychiatric disorders like autoimmune disorders was
available besides that none of the children were schizo-
phrenic. The control group consisted of healthy and typically
developed children with no signs or diagnoses of neuro-
developmental disorders and was recruited from the same
area in order to minimize toxic inﬂuences from different
environments. Children both in the ASD and control groups
who had any kind of infection or disease less than 2 weeks
before the time of examination were excluded.
Blood samples for one healthy control (female) and four
patients (two females and two males) were not possible to
analyze owing to the too small sample volume, resulting in 30
controls and 28 children for children with ASD for further
studies (For participant details, see Table 1). The ASD group
comprised more males and was insigniﬁcantly younger.
The study was approved (MT/1247) by the ethics commit-
tee of the University of Medical Sciences, Tehran.
Procedure. All blood samples were collected by a pediatric
nurse and the children diagnosed with autism were super-
vised by a pediatric psychiatrist with special training in the
ﬁeld of childhood psychosis. Venous blood was collected into
3-ml Heparin tubes (Vacutainer System; Becton-Dickinson,
Plymouth, UK) and plasma was separated immediately
by centrifugation at 1300g for 10min at 41C. Immediately
thereafter, an EDTA-free inhibitor cocktail (Halt protease
inhibitor; Thermo Scientiﬁc Pierce Protein Research Products,
Rockford, IL, USA) and Prefablock SC (Pentapharm, Munich,
Germany) were added at a concentration of 10mlml
 1
plasma and 20mlml
 1 plasma, respectively. The produced
plasma was aliquoted in small portions and immediately
frozen on dry ice and stored at  801C.
Peptide proﬁling. SELDI-TOF mass spectrometry (MS) was
used to proﬁle low-molecular weight peptides, less than 10kDa,
in the plasma of children with ASD and the healthy control
group, suitable for the subsequent MS/MS analysis (described
below) by matrix-assisted laser desorption/ionization
(MALDI)-TOF/TOF MS and post source decay fragmentation.
Carboxy methyl CM10 protein chip array surfaces (a weak-
cation exchanger bearing the COOH functional group) with
eight application spots were prepared according to the
manufacturer’s protocol (BioRad, Hercules, CA, USA). CM10
protein chip arrays were equilibrated twice with 100ml buffer
(0.1M sodium acetate, pH 5.0) for 5min at 251C. Plasma
samples diluted 1:50 with sodium phosphate buffer (25mM,
pH 7.0) were applied onto the bioprocessor well. After 45min
Figure 1 Crystal structure of complement protein C3 (C3b/A/1) with location of
C3fdomain.LocationofC3fdomain(boxed)instructuremodelfromPyMol(DeLano
Scientiﬁc LLC, San Carlos, CA, USA).
Table 1 Participant details
ASD
(n¼28)
Controls
(n¼30)
Difference
P
a
Gender
Males 23 14
Females 5 16 0.007
Age
Mean (s.d.) 5.0 (1.7) 6.1 (2.3)
Median (range) 5 (3–9) 6 (3–12) 0.060
Medication
Risperdal only or in combination 18 0 —
Ritalin only or in combination 4 0 —
No speciﬁc medication 6 30 —
Abbreviation: ASD, autism spectrum disorders.
aFisher’s exact test for categorical and Mann Whitney’s U-test for continuous
parameters.
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Translational Psychiatryof incubation with shaking at 251C samples were washed
three times with 150ml of dilution buffer, followed by two
quick rinses with 150mlo f1m M HEPES buffer, pH 7.0. The
chip array was removed from the bioprocessor, air-dried and
0.8ml of saturated (25mg/ml) CHCA (a-cyano-4-hydroxy-
cinnamic acid; BioRad) was added to each spot, allowed to
air-dry, and this step was repeated once. The chip array was
read on BioRad protein chip reader (PCS 4000) on SELDI
system personal edition. Before reading the chip arrays an
external calibration was performed by use of ‘all-in-one
peptide standard’ (BioRad) containing a mixture of seven
different peptides in the molecular range of 1–7kDa.
Sequencing of peptides. 100ml of plasma samples were
diluted with 300mlo f2 5m M sodium phosphate buffer, pH 7.0,
and subjected to ultraﬁltration by use of a 10-kDa Microne
membrane (Millipore, Bedford, MA, USA). Ultraﬁltrate was
dried in a Speed Vacuum centrifuge, reconstituted in 10mlo f
20mM sodium phosphate buffer, pH 7.0, and desalted on
ZipTip C-18 columns (Millipore). Five microliters of the
sample was applied on the prepared SELDI chip, incubated,
washed and dried (as described above). One microliter of
saturated (25mgml
 1) CHCA was added to the spots, allowed
to air-dry, and this step was repeated once.
The MALDI TOF/TOF MS instrument used for sequence
veriﬁcation of the peptides was an Ultraﬂex II TOF/TOF
(Bruker Daltonics GmbH, Bremen, Germany) equipped with a
SmartBeam laser. All spectra were acquired using the reﬂec-
tron mode. To acquire MS/MS spectra, post source decay
TOF/TOF by laser-induced dissociation was performed. The
target of choice for the MALDI approach was a SELDI-TOF
target (BioRad). The prepared matrix/sample spots were
introduced into the Ultraﬂex II and MS spectra were recorded
from each prepared sample spot. The calibration used was an
external near-neighbor calibration. The samples used for
calibration were a mixture of peptides covering the mass
range of 1–5kDa. From the acquired peptide masses (TOF
MS), the candidate peptides were selected manually for
subsequent experiments. Spectra were annotated with data
processing software, FlexAnalysis (Bruker Daltonics GmbH,
Bremen, Germany), and ﬁnally interpreted by software
assisted de novo sequence analysis (BioTools, Bruker
Daltonics GmbH). The results from MALDI TOF/TOF MS
were conﬁrmed by analysis using high-resolution nano-LC-
ESI FTICR MS.
Data analysis and statistics. The peak intensity from the
SELDI TOF mass spectra were analyzed in triplicate and
mean values were calculated. These were log-normally distributed
and the following analyses were, therefore, made using
logarithmic values. Group differences of the individual peaks
were analyzed using Student’s t-test, and for combination of
Figure 2 Typical SELDI TOF-derived mass spectra of plasma from children diagnosed with ASD and control children. Non-hemolytic samples were from three children
diagnosed with ASD (d-1, d-2, d-3) and from three control children (c-1, c-2, c-3). The analysis was a blind test with the identities of the children unknown. Following analysis
the identities of the children were revealed: d-1 (male, age 5), c-1 (female, age 5), d-2 (male, age 6), c-2 (male, age 7), d-3 (female, age 4) and c-3 (female, age 5). The
positions of the three peptides, 1864±1, 1978±1, and 2020±1Da, are indicated.
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39
Discrimination analysis gives a linear combination of three
peaks (composite variable) that maximizes the distance
between the mean values of the two groups (the so-called
general distance) that is calculated as (zA–zB/O variance of z
between groups, where zA and zB are the mean values for
the two groups A and B for a speciﬁc set of parameters (ASD
index). Because of uncertainties of the impact of hemolysis,
40
the analysis was made using non-hemolytic samples only
(n¼49), but the ASD index was calculated for all subjects
(Table 3). Receiver operating characteristic curves
41 were
then constructed for all 58 subjects and for those 49 without
hemolysis (Figure 3). Of all 58 participants comprising 30
control children and 28 children in the ASD group, 11
‘outliers’, 7 in the control group and 4 in the ASD group, were
identiﬁed. Of the 49 participant samples without hemolysis
(27 control children and 22 ASD group children) ﬁve ‘outliers’,
four in the control group and one in the ASD group, were
observed. Fisher’s exact test was used to test differences
between sex and age-categories, and age differences were
also tested with Mann–Whitney’s U-test (Table 1). For
receiver operating characteristic analysis the statistical
program MedCalc (version 6.10, 2001; Frank Schoonjans,
Mariakerke, Belgium) was used and all other statistical analyses
were carried out using Statistica (version 8, Statsoft, Tulsa, OK,
USA). A P-value of less than 0.05 was considered signiﬁcant.
Results
The results show signiﬁcant group differences of the intensity
of the three different peaks with mass to charge ratios (m/z)
1864, 1978, and 2020±1Da (Figure 2; Table 2) both in
univariate(individualpeaks;notshown)andinthemultivariate
(composite peaks) analysis (Table 3; Figure 3). The peaks
with an m/z of 1864 and 2020±1Da were upregulated and
overrepresented in children with ASD, whereas the peptide of
1978±1Da was downregulated in the children with ASD as
comparedwiththehealthycontrolchildren.Thepeptideswere
selectedbasedontheirdiscriminatingabilities.Inaddition,the
mass and intensity of the peptides is determining the
possibility to subsequently identify and sequence them with
MALDI-TOF/TOF MS and ESI-FTICR MS. From the acquired
peptide masses (SELDI TOF MS data), the candidate
peptides, for example, those with an m/z of 2020±1, were
selected (Figure 4) and the amino-acid sequences were
determined using tandem MS (MALDI TOF/TOF MS) as
shown in Table 2. These sequences were also conﬁrmed by
nano-LC-ESIFTICRMS (notshown).Theﬁrst peptidewith an
m/z of 2020±1Da consists of 17 amino-acid residues
corresponds to the peptide known as C3f (NCBI accession
number 1413205A) of the complement protein C3 (Figure 1).
Thesecondpeptidewithanm/z of 1864±1Da corresponds
to a peptide of 16 residues with the same sequence as C3f
but lacks the C-terminal arginine and is known as C3f-
desArg. The third peptide with an m/z of 1978±1Dathat
appears at higher concentration in the group of healthy
control childrenhas thesame sequence asC3f but carries a
Table 2 Peptides that expressed differentially in children with ASD in
comparison with the control children
Average
mass
Monoisotopic
mass
Sequence P-value
2021.31 2020.10 SSKITHRIWHESASLLR o0.001
1865.12 1864.00 SSKITHRIWHESASLL 0.003
1979.27 1978.08 SSKITHRIWHESASLLR* 0.026
Abbreviation: ASD, autism spectrum disorders.
R*: modiﬁed arginine residue at the C-terminal of C3f where arginine loses
NH¼C-NH2 moiety at the R-chain.
P-values calculated by log value and Student’s t-test.
Table 3 Results from ROC curve analysis showing individual peaks and the composite variable (combined) for all subjects (top) and those without sample hemolysis
(bottom).
All subjects (n¼58) Combined
2021Da 1865Da 1979Da
ROC area (AUC) 0.724 0.745 0.668 0.814
95% CI 0.591–0.833 0.614–0.850 0.532–0.786 0.690–0.904
P-value
a o0.001 o0.001 0.018 o0.001
Cutoff values
b 45.40 43.10 p4.53 43.92
Sens/spec 54/93 89/57 75/63 86/77
Cutoff values
b 45.22 43.52 p3.88 44.33
Sens. at spec. X80% 64/80 57/80 32/87 79/83
Samples without hemolysis (n¼49)
ROC area (AUC) 0.818 0.754 0.749 0.923
95% CI 0.682–0.914 0.610–0.866 0.605–0.862 0.809–0.979
P-value
a o0.001 o0.001 o0.001 o0.001
Cutoff values
b 45.13 43.10 p4.50 44.21
Sens/spec 82/74 91/52 82/67 95/85
Cutoff values
b 45.22 43.54 p4.07 44.21
Sens. at spec. X80% 73/81 55/81 50/81 95/85
Abbreviations: ASD, autism spectrum disorders; AUC, area under the curve; CI, conﬁdence interval; ROC, receiver operating characteristic; sens., sensitivity; spec.,
speciﬁcity.
aAUC different from 0.5.
bLogarithm of peak energy.
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C-terminus.
The results show a signiﬁcant difference between the mean
of the an m/z values of these peptide intensities from children
with ASD and the control group with P-values o0.05 of the
selected peptides (Table 2).
Discussion
Before starting this study, different aspectsthat might have an
impact on the resulting spectra such as collection, handling
and processing of samples, including choice of protease
inhibitors, temperature, freezing and thawing cycles have
been evaluated. We believe that the optimized procedures
during the sample handling secure reproducible spectra of
good quality. In collection of serum samples, it is not
uncommon to have hemolytic events due to rupturing of red
blood cells during the processing steps. We noticed that, of
the 58 subjects, 9 showed moderate hemolysis and were
subjected to separate statistical evaluation. Hemolysis in the
samples was evaluated by examination of the mass peaks at
7.6 and 15.1kDa corresponding to the double-charged and
single-charged a-subunit of hemoglobin, respectively.
40 To
avoidinterferenceofthehemoglobinsubunitsintheproteomic
proﬁling of the multiple serum specimens where the subunits
may compete for or alter the binding afﬁnity of other serum
proteins to the surface
40 samples with values 480 were
excluded (see Table 3 and Figure 3). In the ASD group some
childrenwithsevereautismwereonmedicationwithRisperdal
to reduce hyperactivity and violent behavior, and a few
children were on medication with Ritalin to improve attention
(Table 1). It would have been ethically questionable to
discontinue the medication with the purpose of controlling
the research design. Although we did not see any detectable
correlation between medication and the presence of the
biomarker peptides in plasma samples of the ASD children it
can not be excluded that some differences may be inﬂuenced
by medications, as previously discussed.
35 In a recently
published study on complement factor I activity,
42 we could
Figure 3 Receiver operating characteristic curves for all 58 subjects and for
those 49 corrected for hemolysis. A composite of data for the peptides 1864±1,
1978±1 and 2020±1 in the group of 58 participants (hatched line) and in the
group of 49 non-hemolytic participants (solid line). For the group of non-hemolytic
participants, sensitivity and speciﬁcity is 95.5 and 85.2, respectively. Criterion value
is 44.2068. Differences between curves, 0.923–0.814¼0.109, is not statistically
signiﬁcant (P¼0.141).
Figure 4 Typical MALDI TOF/TOF mass spectrum for sequence analysis. Fragmentation of C3f (2020.1Da) to C3f-des-arginine (1864.2Da) is identiﬁed with
monoisotopic mass of arginine of 174.8 (MþH
þ), and to C3f-modiﬁed arginine (1978.1Da).
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subjectsinthisstudy.OnlysixofthechildrenintheASDgroup
had no medication. Of these ﬁve were correctly classiﬁed in
thediscriminationanalysisand1wasasamplewithhemolysis
and was incorrectly classiﬁed. Of the three biomarkers,
2020±1, 1978±1 and 1864±1, identiﬁed in this proteomic
proﬁling study of children with ASD and control children, the
1978-kDa ornithine-containing peptide identiﬁed by tandem
MS is interesting as is suggest that the arginine of the 2020-
kDa peptide is recognized as a target for enzymatic con-
version. As arginase requires a free arginine for conversion to
ornithine
43 an interesting alternative possibility is that this
C-terminalarginineresidueisADP-ribosylatedbyanarginine-
speciﬁc ADP-ribosyltransferase (ART) catalyzing the tran-
sfer of ADP-ribose from NAD
þ (ref. 44) with the possibility of
a ‘secondary’ modiﬁcation of the ADP-ribosylated arginine
resulting in replacement of ADP-ribosylarginine by ornithine
as shown for HNP-1.
45 Lack of ART expression, that is
ART2, has previously been correlated with enhanced sus-
ceptibility to autoimmune diseases (see Laing et al.
44 and
references therein). Altered immune function and comple-
ment-system deﬁciency has been reported for children with
ASD indicating a recurrent incidence of immunological
diseases.
46–50 Other investigations has shown signiﬁcantly
increased levels of inﬂammatory markers such as TNF-a,
IL-6,IL-8,GM-CSFandIFN-g inthepostmortembraintissue
of individuals with autism and immune dysfunction has also
been proposed as a potential mechanism for the pathogen-
esis of ASD.
21,51,52
By the proteomic approach used in this study we have
identiﬁed differentially expressed peptides that correspond to
fragments of the C3 complement protein. Although the study
was based on a relatively limited group of children it demo-
nstrates the potential of the proteomic approach in which
the relevance and potential diagnostic utility of the panel of
biomarkers was further strengthened by known associations
between the protein or peptides and pathogenesis of ASD. By
use of the proteomic approach we have discovered a unique
set of biomarkers, which carries the potential for an early
detection of ASD with an improved diagnostic accuracy that
would enable an early intervention in the development of this
disorder.
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